DE602006011959D1 - Na+, k+-atpase-expression bei zervixdysplasie und -krebs - Google Patents

Na+, k+-atpase-expression bei zervixdysplasie und -krebs

Info

Publication number
DE602006011959D1
DE602006011959D1 DE602006011959T DE602006011959T DE602006011959D1 DE 602006011959 D1 DE602006011959 D1 DE 602006011959D1 DE 602006011959 T DE602006011959 T DE 602006011959T DE 602006011959 T DE602006011959 T DE 602006011959T DE 602006011959 D1 DE602006011959 D1 DE 602006011959D1
Authority
DE
Germany
Prior art keywords
cervical
dysplasia
atpase
cancer
expression
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
DE602006011959T
Other languages
English (en)
Inventor
Hiroaki Nitta
Thomas M Grogan
Phillip Miller
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Ventana Medical Systems Inc
Original Assignee
Ventana Medical Systems Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Ventana Medical Systems Inc filed Critical Ventana Medical Systems Inc
Publication of DE602006011959D1 publication Critical patent/DE602006011959D1/de
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/574—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • G01N33/57407—Specifically defined cancers
    • G01N33/57411—Specifically defined cancers of cervix
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/02—Drugs for genital or sexual disorders; Contraceptives for disorders of the vagina
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Urology & Nephrology (AREA)
  • Biomedical Technology (AREA)
  • Hematology (AREA)
  • Molecular Biology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Cell Biology (AREA)
  • Pathology (AREA)
  • Oncology (AREA)
  • Microbiology (AREA)
  • Hospice & Palliative Care (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Food Science & Technology (AREA)
  • Physics & Mathematics (AREA)
  • Analytical Chemistry (AREA)
  • Biochemistry (AREA)
  • General Physics & Mathematics (AREA)
  • Biotechnology (AREA)
  • Gynecology & Obstetrics (AREA)
  • Endocrinology (AREA)
  • Reproductive Health (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Enzymes And Modification Thereof (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Medicines Containing Plant Substances (AREA)
DE602006011959T 2005-12-30 2006-12-27 Na+, k+-atpase-expression bei zervixdysplasie und -krebs Active DE602006011959D1 (de)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US75522305P 2005-12-30 2005-12-30
US76444706P 2006-02-01 2006-02-01
PCT/US2006/049392 WO2007079128A1 (en) 2005-12-30 2006-12-27 Na+, k+-atpase expression in cervical dysplasia and cancer

Publications (1)

Publication Number Publication Date
DE602006011959D1 true DE602006011959D1 (de) 2010-03-11

Family

ID=38051860

Family Applications (1)

Application Number Title Priority Date Filing Date
DE602006011959T Active DE602006011959D1 (de) 2005-12-30 2006-12-27 Na+, k+-atpase-expression bei zervixdysplasie und -krebs

Country Status (11)

Country Link
US (1) US7851145B2 (de)
EP (1) EP1977246B1 (de)
JP (1) JP4960972B2 (de)
CN (1) CN101360998B (de)
AT (1) ATE456053T1 (de)
AU (1) AU2006332806B2 (de)
CA (1) CA2634896C (de)
DE (1) DE602006011959D1 (de)
ES (1) ES2340206T3 (de)
HK (1) HK1124918A1 (de)
WO (1) WO2007079128A1 (de)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DK2442107T3 (da) 2006-11-01 2014-05-19 Ventana Med Syst Inc Haptener, haptenkonjugater, sammensætninger deraf og fremgangsmåde til deres fremstilling og anvendelse
JP2010509251A (ja) * 2006-11-09 2010-03-25 ユニバイオスクリーン エス．アー． 増殖性疾患の治療におけるＮａ＋、Ｋ＋−ＡＴＰアーゼのアルファ−１またはアルファ−３サブユニットの標的化
ES2731432T3 (es) 2007-05-23 2019-11-15 Ventana Med Syst Inc Transportadores poliméricos para inmunohistoquímica e hibridación in situ
GB0720113D0 (en) * 2007-10-15 2007-11-28 Cambridge Cancer Diagnostics L Diagnostic, prognostic and predictive testing for cancer
RU2571687C2 (ru) * 2007-11-13 2015-12-20 Феникс Байотекнолоджи Инк. Набор для определения вероятности терапевтического ответа на противораковую химиотерапию сердечным гликозидом
ES2557594T3 (es) 2008-06-05 2016-01-27 Ventana Medical Systems, Inc. Método para el procesamiento histoquímico y el uso de una composición para el procesamiento histoquímico
US20130107066A1 (en) * 2011-10-27 2013-05-02 Qualcomm Incorporated Sensor aided video stabilization
WO2017013637A1 (en) 2015-07-19 2017-01-26 Yeda Research And Development Co. Ltd. Selective inhibitors of alpha2-containing isoforms of na,k-atpase and use thereof for reduction of intraocular pressure
EP3325494B1 (de) 2015-07-19 2020-12-30 Yeda Research and Development Co., Ltd. Selektive inhibitoren der alpha2-haltigen isoformen der na, k-atpase und deren verwendung zur reduzierung des augeninnendruckes

Family Cites Families (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE69734060T2 (de) 1996-05-24 2006-06-29 Angiotech Pharmaceuticals, Inc., Vancouver Zubereitungen und verfahren zur behandlung oder prävention von krankheiten der körperpassagewege
AU6764398A (en) 1997-03-20 1998-10-12 Variagenics, Inc. Target genes for allele-specific drugs
AU734226B2 (en) 1997-11-10 2001-06-07 Regents Of The University Of California, The Biochemical methods for detecting cervical dysplasia and cancer
US6380167B1 (en) 1999-02-12 2002-04-30 Primecyte, Inc. Methods for anti-tumor therapy
GB0010683D0 (en) * 2000-05-03 2000-06-28 Univ Bristol Cancer therapy
JP2003219880A (ja) * 2001-01-30 2003-08-05 Takeda Chem Ind Ltd 新規タンパク質およびそのｄｎａ
US6703400B2 (en) 2001-02-23 2004-03-09 Schering Corporation Methods for treating multidrug resistance
US20030232350A1 (en) 2001-11-13 2003-12-18 Eos Biotechnology, Inc. Methods of diagnosis of cancer, compositions and methods of screening for modulators of cancer
WO2003086292A2 (en) * 2002-04-08 2003-10-23 The Regents Of The University Of California Use of na,k-atpase a-and b-subunits in bladder cancer detection and drug screening
US6922586B2 (en) 2002-05-20 2005-07-26 Richard J. Davies Method and system for detecting electrophysiological changes in pre-cancerous and cancerous tissue
JP2006514823A (ja) * 2002-08-20 2006-05-18 ミレニアム ファーマスーティカルズ インク 子宮頸癌の同定、評価、予防および治療を行うための組成物、キットおよび方法
CA2488224A1 (en) * 2003-04-03 2004-10-21 Alnylam Pharmaceuticals, Inc. Irna conjugates
US20050250709A1 (en) * 2003-12-19 2005-11-10 Bionaut Pharmaceuticals Anti-neoplastic agents, combination therapies and related methods
US20050282893A1 (en) 2004-01-30 2005-12-22 Au Jessie L Methods and compositions for using suramin, pentosan, polysulfate, telomerase antisense and telomerase inhibitors
MXPA06011020A (es) * 2004-03-24 2007-08-14 Tripath Imaging Inc Metodos y composiciones para la deteccion de una enfermedad cervical.
WO2006021817A2 (en) 2004-08-23 2006-03-02 Sylentis S.A.U. Treatment of eye disorders characterized by an elevated introacular pressure by sirnas
US20060135468A1 (en) 2004-09-02 2006-06-22 Bionaut Pharmaceuticals, Inc. Treatment of refractory cancers using NA+/K+ ATPase inhibitors
US20060205679A1 (en) 2004-10-22 2006-09-14 Azaya Therapeutics, Inc. Topical and oral formulations of cardiac glycosides for treating skin diseases
TW200639252A (en) 2005-02-01 2006-11-16 Alcon Inc RNAi-mediated inhibition of ocular hypertension targets
US7582441B1 (en) * 2005-10-17 2009-09-01 Celera Corporation Methods and compositions for treating and diagnosing disease

Also Published As

Publication number Publication date
ATE456053T1 (de) 2010-02-15
AU2006332806B2 (en) 2012-03-15
CN101360998B (zh) 2015-12-02
US7851145B2 (en) 2010-12-14
US20080286386A1 (en) 2008-11-20
EP1977246B1 (de) 2010-01-20
JP2009522551A (ja) 2009-06-11
AU2006332806A8 (en) 2011-10-20
CA2634896C (en) 2018-08-07
ES2340206T3 (es) 2010-05-31
JP4960972B2 (ja) 2012-06-27
AU2006332806A1 (en) 2007-07-12
CA2634896A1 (en) 2007-07-12
EP1977246A1 (de) 2008-10-08
WO2007079128A1 (en) 2007-07-12
CN101360998A (zh) 2009-02-04
HK1124918A1 (zh) 2009-07-24

Similar Documents

Publication Publication Date Title
DE602006011959D1 (de) Na+, k+-atpase-expression bei zervixdysplasie und -krebs
EP2575884A4 (de) Anwendungen und zusammensetzungen zur behandlung von acne inversa
ATE456571T1 (de) Proteasom-hemmer und verwendungsverfahren dafür
EP3447491A3 (de) Diagnose und behandlungen im zusammenhang mit th2-hemmung
ATE489957T1 (de) Mittel zur behandlung von entzündlichen erkrankungen
EA201070636A1 (ru) Ингибирование рецептора белка, стимулирующего макрофаги (ron), и способы его лечения
NO20064976L (no) Azanidoler som er nyttige som inhibitorer av rock og andre proteinkinaser
NO20060398L (no) Anvendelse av en kombinasjon av en epidermal vekstfaktor reseptor kinase inhibitor og cytotoksiske midler for behandling og hemming av kreft
WO2005112981A3 (en) Compositions and methods for the stimulation or enhancement of bone formation and the self-renewal of cells
MY160041A (en) Compositions and methods for treating parasitic infections
PL2231636T3 (pl) Pochodne pirazolowe i ich zastosowanie jako inhibitorów kinaz zależnych od cyklin
EA200971053A1 (ru) Способы лечения кожных язв
EA201290267A1 (ru) Производные диоксабицикло[3.2.1]октан-2,3,4-триола
WO2006075095A3 (fr) Utilisation de derives de la purine comme inhibiteurs de la proteine hsp90 et pour le traitement du cancer
EA201170160A1 (ru) Новые ингибиторы пролиферации и активации переносчика сигнала и активатора транскрипции (stats)
EP4275752A3 (de) Behandlung von erkrankungen im zusammenhang mit sucht und impulskontrolle mittels pde7-inhibitoren
TW200722090A (en) Compounds useful for inhibiting chk1
EA201100874A1 (ru) Соединения для лечения рака
WO2021203103A3 (en) Ace2 receptor polymorphisms and varying susceptibility to sars-cov-2, methods for diagnosis and treatment
EP2563794A4 (de) Hemmer der protein-tyrosin-kinase-aktivität und ihre verwendung zur behandlung von augenerkrankungen
MX2007010484A (es) Moleculas y metodos para usarlas para tratar enfermedades asociadas con mcp-1/ccr2.
HK1205677A1 (en) Mesenchymal stem cells and uses therefor
MX2010009488A (es) Métodos para modular la actividad del receptor de mc5, y tratamiento de las afecciones relacionadas con este receptor.
WO2011091154A3 (en) Use of human erythrocytes for prevention and treatment of cancer dissemination and growth
MX2022004270A (es) Inhibidores de aldosa reductasa para el tratamiento de la deficiencia de fosfomannomutasa 2.

Legal Events

Date Code Title Description
8364 No opposition during term of opposition